ProfileGDS5678 / 1426441_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 26% 26% 28% 29% 29% 28% 25% 36% 28% 29% 27% 27% 27% 27% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6265826
GSM967853U87-EV human glioblastoma xenograft - Control 22.5992426
GSM967854U87-EV human glioblastoma xenograft - Control 32.6362328
GSM967855U87-EV human glioblastoma xenograft - Control 42.6087629
GSM967856U87-EV human glioblastoma xenograft - Control 52.6136229
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7010928
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6195225
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8024236
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6101528
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6509229
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6173627
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5963627
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6231127
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6229927